Literature DB >> 7046988

Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.

L J Rubin, B M Groves, J T Reeves, M Frosolono, F Handel, A E Cato.   

Abstract

To evaluate the effects of prostacyclin (prostaglandin I2) on pulmonary vascular tone in primary pulmonary hypertension (PPH), we performed right-heart catheterization on seven patients with PPH and made hemodynamic measurements before and after infusing incremental doses of prostacyclin. In maximal doses of 2-12 mg/kg/min (mean 5.7 +/0 3.1 ng/kg/min), prostacyclin reduced mean pulmonary arterial pressure from 62 +/- 15 to 55 +/- 16 mm Hg (p less than 0.05) and total pulmonary resistance from 17.1 +/- 8.7 to 9.7 +/- 5.9 units (p less than 0.005), and increased cardiac output from 4.22 +/- 1.64 to 6.57 +/- 2.04 l/min (p less than 0.01). Heart rate increased from 83 +/- 13 to 94 +/- 11 beats/min (p = 0.1) and mean systemic arterial pressure decreased from 90 +/- 12 to 77 +/- 4 mm Hg (p = 0.055). Three patients who received a continuous infusion of prostacyclin for 24-48 hours had sustained reductions in total pulmonary resistance during the infusion period. These data demonstrate that prostacyclin can increase cardiac output and reduce pulmonary arterial pressure and resistance in PPH.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7046988     DOI: 10.1161/01.cir.66.2.334

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  56 in total

Review 1.  Primary pulmonary hypertension.

Authors:  A J Peacock
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

Review 2.  Pulmonary hypertension: its assessment and treatment.

Authors:  S Brij; A J Peacock
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

3.  Recommendations on the management of pulmonary hypertension in clinical practice.

Authors: 
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

Review 4.  Treatment of pulmonary hypertension secondary to connective tissue diseases.

Authors:  O Sanchez; M Humbert; O Sitbon; G Simonneau
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

Review 5.  [Consensus recommendations of the Pulmonary Arterial Hypertension Study Group of the Austrian Society of Lung Diseases and Tuberculosis].

Authors:  Rolf Ziesche
Journal:  Wien Klin Wochenschr       Date:  2003-05-30       Impact factor: 1.704

Review 6.  Cor pulmonale in cystic fibrosis.

Authors:  M H Götz; O C Burghuber; U Salzer-Muhar; W Wolosczuk; M Weissel; E Hartter
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

7.  The treatment of primary pulmonary hypertension.

Authors:  N G Uren; C M Oakley
Journal:  Br Heart J       Date:  1991-08

Review 8.  Drug treatment of primary pulmonary hypertension.

Authors:  A A McLeod; D E Jewitt
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

9.  [Aerosolized and intravenous prostacyclin during one-lung ventilation. Hemodynamic and pulmonary effects].

Authors:  M Bund; D Henzler; R Walz; R Rossaint; S Piepenbrock; R Kuhlen
Journal:  Anaesthesist       Date:  2004-07       Impact factor: 1.041

10.  Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.

Authors:  Stephanie L Siehr; D Dunbar Ivy; Kathleen Miller-Reed; Michelle Ogawa; David N Rosenthal; Jeffrey A Feinstein
Journal:  J Heart Lung Transplant       Date:  2013-02-28       Impact factor: 10.247

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.